US · BBNX · MEDICAL - DEVICES
Beta Bionics, Inc. (BBNX) intrinsic value and stock valuation
$13.36as of 2026-11-21 · Mkt cap 625.81M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Beta Bionics, Inc. DCF and intrinsic value
InvestorsCraft values BBNX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from BBNX’s statements →
Beta Bionics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2022–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12M | $180K |
| Operating income | -$-71.68M | -$-45.25M | -$-35.85M | -$-65.84M |
| Net income | -$-73.2M | -$-54.76M | -$-44.1M | -$-64.75M |
| EPSd | -$-1.81M | -$-1.28M | -$-1.03M | -$-1.51M |
| Operating cash flow | -$-50.92M | -$-48.27M | -$-32.45M | -$-60.21M |
| Capital expenditure | -$-5.3M | -$-3.4M | -$-400K | -$-770K |
| Free cash flow | -$-56.22M | -$-51.67M | -$-32.85M | -$-60.98M |
| Total assets | $328.7M | $149.7M | $110M | $35.5M |
| Total debt | $7.3M | $7.25M | $4.22M | $4.13M |
| Net debt | -$-24.27M | -$-23.18M | -$-22.34M | -$-23.54M |
| Total equity | $287.6M | $76M | $58.6M | -$-170.03M |
| Cash and short-term investments | $219.1M | $103.6M | $96.8M | $27.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12M | $180K |
| Cost of revenue | $44.7M | $29.2M | $5.69M | $0.00 |
| Gross profit | $55.5M | $35.9M | $6.31M | $180K |
| Research and development expenses | $34.8M | $26.2M | $17.9M | $31.4M |
| Selling, general and administrative expenses | $92.4M | $55M | $24.2M | $33.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $1.1M |
| Operating expenses | $127.2M | $81.1M | $42.2M | $66M |
| Cost and expenses | $171.9M | $110.4M | $47.8M | $66M |
| Interest income | $10.9M | $3.91M | $1.78M | $200K |
| Interest expense | $0.00 | $0.00 | $0.00 | $10K |
| Depreciation and amortization | $2.88M | $1.15M | $1.23M | $1.34M |
| Ebitda | -$-70.32M | -$-53.6M | -$-42.87M | -$-63.4M |
| Operating income | -$-71.68M | -$-45.25M | -$-35.85M | -$-65.84M |
| Total other income/expenses, net | -$-1.52M | -$-9.51M | -$-8.25M | $1.09M |
| Income before tax | -$-73.2M | -$-54.76M | -$-44.1M | -$-64.75M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-73.2M | -$-54.76M | -$-44.1M | -$-64.75M |
| Weighted average shares outstanding | $40.5M | $42.9M | $42.9M | $42.9M |
| Weighted average diluted shares outstanding | $40.5M | $42.9M | $42.9M | $42.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Cash and short-term investments | $219.1M | $103.6M | $96.8M | $27.7M |
| Net receivables | $19.9M | $12M | $4.45M | $0.00 |
| Inventory | $21.7M | $13.3M | $1.25M | $0.00 |
| Total current assets | $267.9M | $132.9M | $103.6M | $28.5M |
| Property, plant and equipment, net | $15.2M | $11.4M | $6.2M | $6.87M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $45.4M | $0.00 | $100K | $0.00 |
| Total non-current assets | $60.8M | $16.7M | $6.42M | $7.06M |
| Total assets | $328.7M | $149.7M | $110M | $35.5M |
| Accounts payable | $5M | $2.85M | $1.17M | $430K |
| Short-term debt | $1.94M | $1.53M | $1.22M | $980K |
| Deferred revenue | $1.56M | $940K | $90K | $0.00 |
| Total current liabilities | $30.9M | $21.2M | $10.6M | $8.87M |
| Long-term debt | $5.37M | $5.73M | $3M | $3.16M |
| Deferred revenue, non-current | $3.3M | $1.86M | $260K | $0.00 |
| Total non-current liabilities | $10.2M | $52.5M | $40.8M | $196.7M |
| Capital lease obligations | $7.3M | $7.25M | $3M | $4.13M |
| Total liabilities | $41.1M | $73.6M | $51.4M | $205.6M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-369.94M | -$-296.74M | -$-229.66M | -$-185.56M |
| Accumulated other comprehensive income (loss) | $400K | $70K | $140K | $0.00 |
| Total equity | $287.6M | $76M | $58.6M | -$-170.03M |
| Total investments | $233M | $73.1M | $70.3M | $0.00 |
| Total debt | $7.3M | $7.25M | $4.22M | $4.13M |
| Net debt | -$-24.27M | -$-23.18M | -$-22.34M | -$-23.54M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Net income | -$-73.2M | -$-54.76M | -$-44.1M | -$-64.75M |
| Depreciation and amortization | $2.88M | $2.28M | $2.09M | $2.09M |
| Stock-based compensation | $16.4M | $6.38M | $5.66M | $6.1M |
| Change in working capital | -$-8.99M | -$-12.15M | -$-5.3M | -$-2.79M |
| Accounts receivable | -$-5.16M | -$-7.62M | -$-4.49M | $0.00 |
| Inventory | -$-9.88M | -$-11.44M | -$-1.19M | $0.00 |
| Accounts payable | $2.1M | $1.51M | $720K | -$-80K |
| Net cash provided by operating activities | -$-50.92M | -$-48.27M | -$-32.45M | -$-60.21M |
| Investments in property, plant and equipment | -$-5.3M | -$-3.4M | -$-400K | -$-770K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-162.81M | -$-3.48M | -$-69.69M | -$-770K |
| Common stock issued | $214.9M | $100K | $30K | $390K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $214.9M | $55.6M | $101M | $56.8M |
| Net change in cash | $1.14M | $3.87M | -$-1.11M | -$-4.2M |
| Cash at end of period | $31.7M | $30.5M | $26.7M | $27.8M |
| Operating cash flow | -$-50.92M | -$-48.27M | -$-32.45M | -$-60.21M |
| Capital expenditure | -$-5.3M | -$-3.4M | -$-400K | -$-770K |
| Free cash flow | -$-56.22M | -$-51.67M | -$-32.85M | -$-60.98M |
Line items
Line items
Line items
About Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
- CEO
- Sean T. Saint
- Employees
- 423
- Beta
- 3.11
Explore
Frequently asked questions
What is the intrinsic value of Beta Bionics, Inc. (BBNX)?
Beta Bionics, Inc. (BBNX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BBNX undervalued?
BBNX trades at a price of $13.36 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.